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Abstract 
AIMS:  
CD133 expression in cancer is frequently associated with poor outcome. Thyroid carcinomas are rare in childhood and 
adolescence and are associated with a higher risk of recurrence and more metastases than the adult tumours. The aim of 
the study was to assess whether the expression of CD133 in thyroid carcinomas of children, adolescents and young 
adults was correlated with clinical prognostic factors. 
METHODS:  
Tissue microarrays were constructed with 235 tumours coming from 208 young adults with a median age of 28 years 
and 27 children with a median age of 13 years. An immunohistochemical study was performed with anti-CD133 
antibody. CD133 expression was evaluated, using a semiquantitative score based on the percentage of positive cells. 
The mutation status of tumours was evaluated by reverse transcriptase PCR. Three cell lines were used to confirm 
CD133 expression by western blot. 
RESULTS:  
CD133 expression was found in 43% of adult and 37% of child tumours and was confirmed by western blot in cell 
lines. In young adults, the expression of CD133 was significantly more frequent in patients with tumours >3 cm 
(p=0.04) and in patients with lymph node metastases (p=0.02). The expression of CD133 was more frequent in patients 
in whom the tumour presented a BRAF mutation (p=0.03). 
CONCLUSIONS:  
CD133 expression is correlated with tumour size, lymph nodes metastases and BRAF mutations in young adults. The 
presence of these cancer stem cells could offer new therapeutic alternatives for aggressive thyroid cancers. 
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